9 Likes Transparency notification Wellington Brussels (Belgium), 02 January 2025 – 20:00 (CET) – Regulated information Summary of the notification Pursuant to Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it has received a transparency notification from Wellington Management Group LLP (having its registered offices at 280 Congress Street, Boston, MA 02210, USA) on 30 December 2024. Wellington Management Group LLP has notified that, following a disposal of UCB shares with voting rights by its affiliates, its shareholding in UCB SA/NV has decreased and it has crossed the 3% threshold downwards, on 27 December 2024. On 27 December 2024, Wellington Management Group LLP (taking into account the holdings of its affiliates) owned less than 3% of UCB shares with voting rights or equivalent financial instruments of the total number of shares issued by the company (194 505 658), versus 4.99% (9 705 989 UCB shares) in the previous notification dated 15 May 2024. Content of the notification Reason for the notification: Acquisition or disposal of voting securities or voting rights; acquisition or disposal of financial instruments that are treated as voting securities. Notification by: A parent undertaking or a controlling person. Persons subject to the notification requirement: Date on which the threshold is crossed: 27 December 2024. Threshold crossed (in %): 3%. Denominator: 194 505 658. Notified details: Chain of controlled undertakings through which the holding is effectively held: Additional information: Wellington Management Company LLP and Wellington Management International Ltd are investment management companies and can exercise the voting rights at their discretion in the absence of specific instructions from the beneficial owners of the shares. Further information This press release and the detailed transparency notification are available on UCB SA/NV’s website via the following link. An updated overview of the UCB SA/NV large shareholdings will be available on UCB SA/NV’s website via the following link. For further information, contact UCB: Investor Relations Antje Witte T +32 2 559 94 14 antje.witte@ucb.com Corporate Communications Laurent Schots T+32 2 559 92 64 laurent.schots@ucb.com About UCB UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 9,000 people in approximately 40 countries, the company generated revenue of €5.3 billion in 2023. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news Asset Download 020124 - PR Transparency notification Wellington 020124 - PB Transparantieverklaring Wellington 020124 - CdP Notification de transparence Wellington 9 Likes
